Role of Cirrhosis a review article
Abstract
When cell are injured or damaged and die off usually that dead tissue that was previously full of living cells becomes fibrotic meaning it become thickened with heaps and heaps of protein and form scar tissue so when your liver is constantly forced to process alcohol like an alcoholic liver disease or subject to a viral attached for a long time like a virus ( HBV or HCV) or anything else that cause a long term or chronic state of liver cell or hepatocytes destruction and inflammation your liver can become seriously Scarred and damage to the point where it's no longer reversible at which point it's became fibrotic and in the liver we call this process cirrhosis.
References
1. Brooks, D., S. Solway, and W.J. Gibbons, ATS statement on six-minute walk test. Am J Respir Crit Care Med, 2003. 167(9): p. 1287.
2. Ge, D. and Z. You, Expression of interleukin-17RC protein in normal human tissues. Int Arch Med, 2008. 1(1): p. 19.
3. Yu, K., et al., Involvement of epithelial-mesenchymal transition in liver fibrosis. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2018. 24(1): p. 5-11.
4. Caja, L., et al., TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. International journal of molecular sciences, 2018. 19(5): p. 1294.
5. Garbuzenko, D.V., N.O. Arefyev, and E.L. Kazachkov, Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. World journal of gastroenterology, 2018. 24(33): p. 3738-3748.
6. Schuppan, D. and N.H. Afdhal, Liver cirrhosis. Lancet, 2008. 371(9615): p. 838-51.
7. Xia, B., et al., Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis. Medicine, 2018. 97(39): p. e11816-e11816.
8. Chen, H.-L., et al., Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. Journal of biomedical science, 2018. 25(1): p. 75-75.
9. Garcia-Tsao, G., et al., Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010. 51(4): p. 1445-9.
10. Tan, Y.-W., et al., Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature. World journal of gastroenterology, 2018. 24(41): p. 4716-4720.
11. Cadranel, J.F., P. Rufat, and F. Degos, Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology, 2000. 32(3): p. 477-81.
12. Gaur, K. and P. Sakhuja, Progressive familial intrahepatic cholestasis: A comprehensive review of a challenging liver disease. Indian J Pathol Microbiol, 2017. 60(1): p. 2-7.
13. Kurokawa, T. and N. Ohkohchi, Platelets in liver disease, cancer and regeneration. World J Gastroenterol, 2017. 23(18): p. 3228-3239.
14. Freeman, R.B., Jr., et al., The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl, 2002. 8(9): p. 851-8.
15. Moore CM, Van Thiel DH. Cirrhotic ascites review: pathophysiology, diagnosis and management. World J Hepatol. 2013;5:251–263. doi: 10.4254/wjh.v5.i5.251. [PMC free article] [PubMed] [CrossRef].
2. Ge, D. and Z. You, Expression of interleukin-17RC protein in normal human tissues. Int Arch Med, 2008. 1(1): p. 19.
3. Yu, K., et al., Involvement of epithelial-mesenchymal transition in liver fibrosis. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2018. 24(1): p. 5-11.
4. Caja, L., et al., TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. International journal of molecular sciences, 2018. 19(5): p. 1294.
5. Garbuzenko, D.V., N.O. Arefyev, and E.L. Kazachkov, Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. World journal of gastroenterology, 2018. 24(33): p. 3738-3748.
6. Schuppan, D. and N.H. Afdhal, Liver cirrhosis. Lancet, 2008. 371(9615): p. 838-51.
7. Xia, B., et al., Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis. Medicine, 2018. 97(39): p. e11816-e11816.
8. Chen, H.-L., et al., Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. Journal of biomedical science, 2018. 25(1): p. 75-75.
9. Garcia-Tsao, G., et al., Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010. 51(4): p. 1445-9.
10. Tan, Y.-W., et al., Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature. World journal of gastroenterology, 2018. 24(41): p. 4716-4720.
11. Cadranel, J.F., P. Rufat, and F. Degos, Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology, 2000. 32(3): p. 477-81.
12. Gaur, K. and P. Sakhuja, Progressive familial intrahepatic cholestasis: A comprehensive review of a challenging liver disease. Indian J Pathol Microbiol, 2017. 60(1): p. 2-7.
13. Kurokawa, T. and N. Ohkohchi, Platelets in liver disease, cancer and regeneration. World J Gastroenterol, 2017. 23(18): p. 3228-3239.
14. Freeman, R.B., Jr., et al., The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl, 2002. 8(9): p. 851-8.
15. Moore CM, Van Thiel DH. Cirrhotic ascites review: pathophysiology, diagnosis and management. World J Hepatol. 2013;5:251–263. doi: 10.4254/wjh.v5.i5.251. [PMC free article] [PubMed] [CrossRef].